Skip to content

Released Mar 3, 2016, after the close

10-K filed Mar 3, 2016, 63 days after period end · 0001564590-16-013981

Q4 2015 · 10-K
Revenue$1.08Mno prior Q4 2014 on file+4.9% vs Q3 2015
Net Income-$7.45MN/M vs Q4 2014N/M vs Q3 2015
EPS Diluted-$0.26N/M vs Q4 2014N/M vs Q3 2015
Operating Incomederived-$6,912,000N/M
Operating Cash Flowderived-$6,970,000N/M
Free Cash Flowderived-$7,148,000N/M
Margins · derived
Operating margin-642.4%
Net margin-692.0%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2015Q4 2014Q4 2013Q4 2012
Revenue$1.08M—$0.00$643.00K
Net Income-$7.45M-$6.23M-$5.74M-$4.16M
EPS Diluted-$0.26-$0.30-$0.29-$3.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR